Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) ± topotecan in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A
Dar, S
Borok, R
Lisak, L
Andrews, C
Ekbal, M
Mazzoran, L
Zorat, F
Rifkin, S
Robin, E
Gregory, S
Venugopal, P
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Rush Canc Inst, Chicago, IL 60612 USA
[2] NW Community Hosp, Arlington Hts, IL USA
[3] Ingalls Mem Hosp, Harvey, IL USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1365
引用
收藏
页码：305A / 305A
页数：1
相关论文
共 50 条
  • [41] Nature of Clinical Response and Depth of Molecular Response in Patients With TP53-Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated With Magrolimab With Azacitidine
    Johnson, Lisa
    Zhang, Yajia
    Li, Biao
    Aviles, Lisa
    Daver, Naval G.
    Vyas, Paresh
    Sallman, David A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S362 - S362
  • [42] Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine
    Johnson, Lisa
    Zhang, Yajia
    Li, Biao
    Aviles, Lisa
    Lal, Indu
    Ramsingh, Giri
    Daver, Naval
    Vyas, Paresh
    Sallman, David A.
    BLOOD, 2022, 140 : 6934 - 6935
  • [43] Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study
    Platzbecker, Uwe
    Germing, Ulrich
    Giagounidis, Aristoteles
    Goetze, Katharina
    Kiewe, Philipp
    Mayer, Karin Tina
    Ottmann, Oliver
    Radsak, Markus
    Wolff, Thomas
    Haase, Detlef
    Hankin, Monty
    Wilson, Dawn
    Zhang, Xiaosha
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    BLOOD, 2015, 126 (23)
  • [44] A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE
    Garcia-Manero, G.
    Silverman, L. R.
    Komrokji, R. S.
    Mufti, G. J.
    Seymour, J. F.
    Tsai, K.
    Reiser, D.
    Skikne, B. S.
    Beach, C. L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S28 - S28
  • [45] Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Almeida, Antonio
    Fenaux, Pierre
    Gatterman, Norbert
    Ozawa, Keiya
    Goldberg, Stuart L.
    Weaver, Jerry
    Sugrue, Mary M.
    BLOOD, 2016, 128 (22)
  • [46] Aplicability Of The Predictive Model Of Response To Erythropoetic Stimulating Agents (ESA) From Myelodysplastic Syndromes (MDS) and Analysis Of Response and Overall Survival (OS) In a Series Of 99 Patients (Pts) With Chronic Myelomonocytic Leukemia (CMML) From The Spanish Registry Of MDS and The Dusseldorf-MDS Registry, Germany
    Xicoy, Blanca
    Germing, Ulrich
    Jimenez, Maria-Jose
    Garcia, Regina
    Garcia, Olga
    Pedro, Carme
    Schemenau, Jennifer
    Luno, Elisa
    Medina, Angeles
    Bernal, Teresa
    Neukirchen, Judith
    Gonzalez, Bernardo
    Maria-Teresa, Ardanaz
    Kuendgen, Andrea
    Cedena, Teresa
    Tormo, Mar
    Brunet, Salut
    Valcarcel, David
    Amigo, Luz
    Vicente, Ana
    Ramos, Fernando
    Marta, Callejas
    Arilla, Maria-Jesus
    Diez-Campelo, Maria
    Bailen, Alicia
    Collado, Rosa
    Arnan, Montserrat
    Marco, Victor
    Zamora, Lurdes
    Allegue, Maria-Jose
    Benlloch, Luis
    Sanz, Guillermo
    BLOOD, 2013, 122 (21)
  • [47] Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes)
    Sasaki, Koji
    Jabbour, Elias
    Pemmaraju, Naveen
    Daver, Naval G.
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pierce, Sherry
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [48] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [49] Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Drusbosky, Leylah M.
    Hawkins, Kimberly E.
    Salan, Cesia
    Turcotte, Madeleine
    Anderson, Glenda G.
    Singh, Neeraj Kumar
    Radhakrishnan, Saumya
    Ullal, Yashaswini
    Talawdekar, Anay
    Sikora, Huzaifa
    Nair, Prashant
    Bhowmick, Priyanka
    Abbasi, Taher
    Vali, Shireen
    Zou, Fei
    Farhadfar, Nosha
    Murthy, Hemant S.
    Horn, Biljana N.
    Leather, Helen L.
    Castillo, Paul
    Sawicki, Barry
    Brown, Randy A.
    Norkin, Maxim
    Hiemenz, John W.
    Hsu, Jack W.
    Slayton, William
    Wingard, John R.
    Cogle, Christopher R.
    BLOOD, 2017, 130
  • [50] Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting
    Bewersdorf, Jan Philipp
    Wei, Wei
    Jaiani, Anna
    Patel, Prital
    Mehta, Rajni
    Neparidze, Natalia
    Shallis, Rory M.
    Podoltsev, Nikolai
    Brunner, Andrew M.
    Zeidan, Amer M.
    BLOOD, 2021, 138 : 3701 - +
12345